COVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab

[1] Bosmann M(2020)Complement activation during critical illness: Current findings and an outlook in the era of COVID-19 Am J Respir Crit Care Med 202 163-5

[2] Najjar S(2020)Central nervous system complications associated with SARS-CoV-2 infection: integrative concepts of pathophysiology and case reports J Neuroinflammation 17 231-41

[3] Najjar A(2020)Is COVID-19 associated thrombosis caused by overactivation of the complement cascade? A literature review Thromb Res 194 36-7

[4] Chong DJ(2020)The first case of COVID-19 treated with the complement C3 inhibitor AMY-101 Clin Immunol 215 108450-74

[5] Pramanik BK(2000)The molecular basis of paroxysmal nocturnal hemoglobinuria Haematologica 85 82-4

[6] Kirsch C(2020)Complement inhibition therapy and dialytic strategies in paroxysmal nocturnal hemoglobinuria: The nephrologist’s opinion J Clin Med 9 1261-54

[7] Kuzniecky RI(2019)Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria Ther Adv Hematol 10 2040620719874728-3

[8] Fletcher-Sandersjöö A(2020)Venous thromboembolism in patients with COVID-19: Systematic review and meta-analysis Thromb Res 196 67-3

[9] Bellander B-M(2020)Complement as a target in COVID-19? Nat Rev Immunol 20 343-3

[10] Mastaglio S(2021)Pharmacokinetic and pharmacodynamic evaluation of ravulizumab in adults with severe Coronavirus Disease 2019 Infectious Diseases Therapy 10 1045-undefined

[1] Bosmann M(2020)Complement activation during critical illness: Current findings and an outlook in the era of COVID-19 Am J Respir Crit Care Med 202 163-5

[2] Najjar S(2020)Central nervous system complications associated with SARS-CoV-2 infection: integrative concepts of pathophysiology and case reports J Neuroinflammation 17 231-41

[3] Najjar A(2020)Is COVID-19 associated thrombosis caused by overactivation of the complement cascade? A literature review Thromb Res 194 36-7

[4] Chong DJ(2020)The first case of COVID-19 treated with the complement C3 inhibitor AMY-101 Clin Immunol 215 108450-74

[5] Pramanik BK(2000)The molecular basis of paroxysmal nocturnal hemoglobinuria Haematologica 85 82-4

[6] Kirsch C(2020)Complement inhibition therapy and dialytic strategies in paroxysmal nocturnal hemoglobinuria: The nephrologist’s opinion J Clin Med 9 1261-54

[7] Kuzniecky RI(2019)Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria Ther Adv Hematol 10 2040620719874728-3

[8] Fletcher-Sandersjöö A(2020)Venous thromboembolism in patients with COVID-19: Systematic review and meta-analysis Thromb Res 196 67-3

[9] Bellander B-M(2020)Complement as a target in COVID-19? Nat Rev Immunol 20 343-3

[10] Mastaglio S(2021)Pharmacokinetic and pharmacodynamic evaluation of ravulizumab in adults with severe Coronavirus Disease 2019 Infectious Diseases Therapy 10 1045-undefined